NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives $38.25 Average Target Price from Analysts

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has been assigned an average rating of “Moderate Buy” from the six analysts that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $38.25.

Several equities research analysts have issued reports on the stock. D. Boral Capital reissued a “buy” rating and issued a $34.00 price target on shares of NRx Pharmaceuticals in a report on Tuesday, May 5th. Wall Street Zen raised shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, June 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research report on Friday, May 8th. Ascendiant Capital Markets lifted their target price on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the company a “buy” rating in a research report on Monday, April 27th. Finally, HC Wainwright reissued a “buy” rating and issued a $45.00 target price on shares of NRx Pharmaceuticals in a research note on Monday, April 27th.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Bleakley Financial Group LLC bought a new position in shares of NRx Pharmaceuticals during the 4th quarter worth approximately $318,000. Global Retirement Partners LLC acquired a new stake in NRx Pharmaceuticals in the 4th quarter valued at $107,000. One Wealth Management Investment & Advisory Services LLC boosted its stake in NRx Pharmaceuticals by 35.3% in the 4th quarter. One Wealth Management Investment & Advisory Services LLC now owns 37,873 shares of the company’s stock valued at $103,000 after buying an additional 9,882 shares in the last quarter. Sjbenen Advisory LLC bought a new stake in NRx Pharmaceuticals in the fourth quarter valued at $41,000. Finally, Anson Funds Management LP grew its position in NRx Pharmaceuticals by 50.3% in the fourth quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock valued at $8,249,000 after acquiring an additional 1,018,853 shares during the period. 4.27% of the stock is currently owned by institutional investors.

NRx Pharmaceuticals Trading Down 8.3%

Shares of NASDAQ:NRXP opened at $4.11 on Tuesday. NRx Pharmaceuticals has a 1-year low of $1.62 and a 1-year high of $5.05. The firm has a market capitalization of $148.91 million, a PE ratio of -3.77 and a beta of 2.19. The business’s 50 day moving average is $3.95 and its 200-day moving average is $2.84.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its earnings results on Friday, May 15th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. The firm had revenue of $1.07 million during the quarter, compared to analyst estimates of $19.43 million. On average, sell-side analysts predict that NRx Pharmaceuticals will post -0.3 EPS for the current year.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.